Dermatitis, Allergic Contact

Dermatologist shines a light on the latest research in photocontact dermatitis SAN DIEGO, March 8, 2024 /PRNewswire/ -- Sun sensitivity and related skin conditions are often misunderstood. Foods, medications, and skincare products can trigger symptoms like itching, redness, blistering, or burning. One of the most common conditions is photocontact dermatitis, a skin reaction occurring when certain substances come into contact with skin that is exposed to the sun. "Sun sensitivity is a common condition that can negatively impact a person's quality of life," said board-certified dermatologist Brandon Adler, MD, FAAD, an assistant professor of dermatology at Keck School of Medicine at the University of Southern California in Los Angeles, speaking at the American Academy of Dermatology's 2024 Annual Meeting. For many people, sun sensitivity is caused by the things they come into contact with, said Dr. Adler. If you develop rashes, blisters, or skin darkening after making a margarita or chopping vegetables for a salad, some of the ingredients may be to blame, said Dr. Adler. Your skin reaction could be caused by handling fruits and vegetables such as lime, figs and celery, or coming into contact with plants like hogweed and St. John's wort. Certain pain relief medications that are applied to the skin may also cause a photosensitive reaction, as can medications taken by mouth, such as some blood pressure medications like hydrochlorothiazide. While medications applied directly to the skin only cause a rash in the area of the body where it was applied, if a medication taken by mouth causes photosensitivity, it can cause a rash over any part of the body that was not protected from the sun. Reactions often appear as an itchy rash or severe sunburn on areas of the body most exposed to the sun, such as the face, neck, arms, or legs, according to Dr. Adler. To determine the cause of sun sensitivity reactions, dermatologists must consider a variety of individual factors, such as various product exposures and medical history, and less frequently bloodwork or a biopsy of the affected area of the skin. "While we will often prescribe anti-inflammatory medications to treat photocontact dermatitis, the primary treatment is identifying and avoiding the irritant or allergen," said Dr. Adler. "In many cases these are reversible reactions, so if the patient stops using the substance causing the reaction, then they will stop having symptoms and won't need ongoing treatment." Many people incorrectly assume that certain types of sun sensitivity only affect older people with lighter skin types, but recent research indicates that younger people and those with darker skin types are more susceptible than previously believed, according to Dr. Adler. New studies suggest that people with darker skin types are susceptible to two other types of photosensitivity, he said. The first is polymorphous light eruption (PMLE), which appears as tiny bumps or rashes that come and go with sun exposure. The second is chronic actinic dermatitis, which causes year-round rashes affecting the sun-exposed parts of the body due to light sensitivity. The exact causes of PMLE and chronic actinic dermatitis are not fully understood, but they are believed to involve an abnormal immune response to sunlight. While it is important for everyone to protect themselves from the sun, Dr. Adler noted that those with sun sensitivity need to be particularly mindful to seek shade, wear sun-protective clothing, and apply a broad-spectrum, water-resistant sunscreen with an SPF of 30 or higher. "If you notice a rash or blistering on your body after being in the sun, it's important to see a board-certified dermatologist, who can determine whether you have a sun-related skin disorder," said Dr. Adler. "No two patients are the same. A board-certified dermatologist can determine what is causing your sun sensitivity and provide a treatment option that works best for your condition." To find a board-certified dermatologist in your area, visit aad.org/findaderm. More Information Eczema Types: Contact Dermatitis Causes AAD B-Roll Library About the AAD Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram. SOURCE American Academy of Dermatology

TORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that company management will participate in the Barclays 26th Annual Global Healthcare Conference, which is being held in Miami, Florida, from March 12-14, 2024. Attendees interested in meeting with Edesa can request meetings through conference organizers or by contacting the company at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (Nasdaq:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn. Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. Contact: Gary Koppenjan Edesa Biotech, Inc. (289) 800-9600 investors@edesabiotech.com SOURCE: Edesa Biotech, Inc. View the original press release on accesswire.com

TORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company plans to participate in the American Contact Dermatitis Society Annual Meeting on March 7, 2024 and the American Academy of Dermatology Annual Meeting from March 8-12, 2024 in San Diego, California. Attendees interested in meeting with Edesa can request meetings by contacting the company at investors@edesabiotech.com. About Edesa Biotech Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. Edesa is also planning to investigational new drug application for a future Phase 2 study of paridiprubart for pulmonary fibrosis. For its dermatology assets, the company has received regulatory approval to conduct a Phase 2 trial of its EB06 (anti-CXCL10) monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. In addition, Edesa is developing an sPLA2 inhibitor, EB01 (daniluromer), as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. Sign up for news alerts. Connect with us on X (Twitter) and LinkedIn. Edesa Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," "may," "will," "would," "could," "should," "might," "potential," or "continue" and variations or similar expressions. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements. Contact: Gary Koppenjan Edesa Biotech, Inc. (289) 800-9600 investors@edesabiotech.com SOURCE: Edesa Biotech, Inc. View the original press release on accesswire.com